Report Description Table of Contents Industry Report and Statistics (Facts & Figures) - Demand & Sales by Product & Application The global plasma protein therapeutics market will witness a robust CAGR of 7.1%, valued at $27.20 billion in 2021, expected to appreciate and reach $50.4 billion by 2030, confirms Strategic Market Research. Plasma is the liquid element of blood, containing 90 percent of water, excluding platelets and white and red blood cells. Plasma protein therapies treat various chronic, life-threatening, rare, and genetic diseases. Plasma protein therapeutics is a medicine that includes plasma, enzymes, salts, antibodies, proteins, and water, which varies according to various production and processing methods. They are used to treat animal bites, autoimmune & immune deficiencies, neurological & bleeding disorders, and shocks & burns as well. According to the community blood center statistics 2020, 4.5 million Americans need blood transfusion yearly. About 37 % of the U.S. population is eligible to donate blood, and less than 10 percent do it annually. About one in 7 people entering a hospital needs blood, and 43,000 pints of blood are used daily in the U.S. and Canada, with each pint saving up to 3 lives. The industry's primary drivers are the increase in autoimmune disorders, immune deficiency disorders, neurological and bleeding disorders, and the rise in the geriatric population. Key Drivers - Increasing Prevalence of Autoimmune Disorders and the Rise in the Geriatric Population. The rising prevalence of autoimmune disease, immune deficiency disorders, bleeding disorders, and the increasing adoption of plasma protein therapy in neurology with other therapeutic indications drive the market's growth. The National Institute of Health asserts that up to 23.5 million Americans, i.e., more than 7 percent of the population in the U.S., suffer from an autoimmune disease. Furthermore, as per the article published by Genentech, it is estimated that approximately one-third of autoimmune diseases developed are hereditary. The approval of new plasma-derived therapies worldwide will help increase the demand and acceptance of plasma products. The rising demand for advanced therapeutic options is expected to drive market growth. As per the article published in frontiers in medicine titled, "Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence", a meta-analysis of eight studies in a sample size of 1,703 patients, it had been found that convalescent plasma reduced the absolute risk of death by 21% in patients with H1N1 viral infections. Advancements in technology, favorable reimbursement policies, and improved standard of living have led to increased life expectancy, contributing to the rise in the geriatric population. Aging is considered the most significant risk factor for developing cardiovascular and neurological diseases and other chronic diseases. According to the article "Autoimmunity in the Elderly: Insights from Basic Science and Clinics," 1 in 4 Europeans is projected to be 65 or older by 2030. Furthermore, as per the United States population assessment, approximately 3 million anemic people are older than 50 years, and the incidence rate of anemia is greater than 20% at the age of 85 and older. Overall, 11.0% of men and 10.2% of women who are above 65 years are anemic. Restraints - Stringent Regulations and Lack of Reimbursement Policies. Imposing stringent restrictions and regulations regarding plasma therapy for handling plasma protein products and a lack of reimbursement policies might affect the adoption of plasma therapy. These are the key factors restraining the growth of the plasma protein therapeutics market. Opportunities - Increase Awareness and Ease of Regulations. An increase in the awareness of autoimmune diseases (Alpha-1 Antitrypsin Deficiency, Von Willebrand Disease, Antithrombin III Deficiency, cardiopulmonary disease, Chronic Inflammatory Demyelinating Polyneuropathy, hepatitis), organ transplants (liver surgery, pediatric HIV), and cases with burns that cause trauma among people can provide opportunities in the further years. National Institutes of Health asserts that up to 23.5 million Americans (more than 7% of the population) suffer from an autoimmune disease, and the prevalence is rising persistently. The easing of government policies on plasma also can provide ample opportunities for the future growth of the market. Market Analysis Of Different Segments Covered in the Report Based on Product Type C1 esterase Inhibitors Albumins Immunoglobulins Coagulation Factors Plasma Derived Factor Viii Fibrinogen Alpha-1 proteinase inhibitor Human serum protein Based on Application Hereditary Angioedema Hemophilia Hemophilia A Hemophilia B Primary Immunodeficiency Disease Secondary Immunodeficiency Idiopathic Thrombocytopenic Purpura Others (Kawasaki disease, GBS, and Chronic Inflammatory Demyelinating Polyneuropathy) Regional Coverage Analysis North America U.S. Mexico Canada Rest of North America Europe France Germany U.K Spain Italy Rest of Europe Asia Pacific China India South Korea Japan Australia Rest of APAC LAMEA Brazil Saudi Arabia Uruguay Argentina Rest of LAMEA Segments Analysis & Insights Based on Product Type, the immunoglobulin segment dominated the overall market with a steady CAGR during the forecasted period due to the factors like the approval of biologics across clinical indications, ease of administration, and affordable cost of treatment. As per the National Blood Authority Australia 2022, 6,31,468 gm of immunoglobin is dispensed to the patients, out of which 1,41,793 gm of immunoglobin is dispensed to patients with critical conditions. Based on the Application, the Haemophilia segment accounted for the largest industry share of around 45% in 2020. According to the Global Hemophilia Care report, more than 1,125,000 men globally have an inherited bleeding disorder, & 418,000 of those have a severe version of the most undiagnosed disease. One in 4,000 to one in 5,000 males are born with Hemophilia A, and 1 in 20,000 newborn males with Hemophilia B. The factors such as the growing no of life-threatening diseases, increasing geriatric population, changes in eating habits, & adoption of a sedentary lifestyle are driving the segment's overall growth. As per the World Federation of Hemophilia report 2020, out of 393,658 people surveyed for the global health survey, 241,535 people have hemophilia, either Type A or Type B. Based on Region, North America held the most significant share of the plasma protein therapeutics market, with almost 50% of the total industry share in 2020. The higher percentage of the North American region can primarily be attributed to a large existence of the patient base, growing geriatric population, increased adoption of novel therapeutics, availability of well-developed infrastructure for storing and maintaining high-quality source plasma, and many others. The CDC estimates that hemophilia is diagnosed at a very young age in the U.S., with the median age of diagnosis being 36 months for people with mild hemophilia, eight months for those with moderate hemophilia, and one month for those with severe hemophilia. On the other hand, the Asia–Pacific region held the fastest growth rate of the market in 2020. Plasma Protein Therapeutics Market Report Coverage Report Attribute Details Forecast Period 2021-2030 The market size value is 2021 USD 27.20 Billion The revenue forecast in 2030 USD 50.4 Billion Growth rate 7.1% The base year for estimation 2021 Historical data 2017 - 2020 Unit USD Billion, CAGR (2021 - 2030) Segmentation By Product, By Technology, and By Region. By Product Type C1 esterase Inhibitors, Albumins, Immunoglobulins, Coagulation Factors, Plasma Derived Factor Viii, Fibrinogen, Alpha-1 proteinase inhibitor, Human serum protein. By Application Hereditary Angioedema, Hemophilia, Primary Immunodeficiency Disease, Secondary Immunodeficiency, Idiopathic Thrombocytopenic Purpura By Region North America, Europe, Asia Pacific, and LAMEA Country Scope U.S., Canada, France, Germany, U.K., China, Japan, India, South Korea, Mexico, Brazil, U.A.E., etc. Company Usability Profiles Octapharma USA Inc., Grifols, SA, Biotest AG, Takeda Pharmaceutical Company Ltd, Baxter, China Biologic Products Holdings Inc., al Company Ltd, Octapharma USA Inc., Shrie Plc, Grifols SA, CSL Behring Plasma Protein Therapeutics Market Competitive Landscape Analysis: The competitive landscape analysis provides information about the crucial competitors prevailing in the global environment. The comparison is performed based on key development strategies, novel drug development, expanding plasma collection networks, market ranking analysis, overall revenue generation, market initiatives, company overview, investment in R&D, company financials, company strengths and weaknesses, global presence, production capacity, production sites, facilities, market potential, etc. Takeda Pharmaceutical Company Ltd Octapharma USA Inc. Grifols, SA Biotest AG Baxter China Biologic Products Holdings Inc. al Company Ltd Octapharma USA Inc. Shrie Plc Grifols SA CSL Behring Recent Developments On August 2022, Daiichi Sankyo, a Japanese company, launched a chemotherapy drug called Enhertu, which received FDA approval as the 1st HER2-directed plasma protein therapy in the world for patients who were previously diagnosed with the HER2 mutant-metastatic non-small-cell lung cancer. It reported an overall response rate of around 57.7% by the patients suffering from the HER2 mutant disease. Biotest became Germany's first plasma protein producer to make an investigational hyper immunoglobulin preparation against COVID-19 in February 2021. The aim was to speed up the development of a potential treatment, improve its chances of success, and expand its supply. Grifols SA collaborated with GC Pharma Group in July 2020 to acquire its Montreal-based plasma fractionation facility, two purification facilities, and 11 plasma collection centers in the United States. This collaboration is to support domestic self-sufficiency and security of plasma-protein-product supply and to become Canada's only large-scale commercial manufacturer of plasma products, with a fractionation capacity of 1.5 million liters per year. On July 2020, Grifols, a global healthcare company and one of the world's top producers of plasma-derived medicines, declared that it had implemented the purchase arrangements with the South Korean-based GC Pharma (Group) whereby Grifols will acquire the Montreal-based plasma fractionation facility and two purification facilities, along with 11 U.S.-based plasma collection centers for a total amount of USD 460 Mn. In April 2020, Kedrion Biopharma collaborated with Kamada Ltd. to manufacture, develop, and distribute a human plasma-derived Anti-SARS-CoV-2 (COVID-19) polyclonal immunoglobulin (IgG) product which will be a probable cure for COVID-19 patients. The product is developed and manufactured using Kamada's proprietary IgG platform technology. Frequently Asked Question About This Report What is plasma protein therapeutics market size? The plasma protein therapeutics market size was USD 27.20 billion in 2021 and is predicted to reach USD 50.4 billion by 2030 with a CAGR of 7.1%. How big is the plasma protein therapeutics market? The global plasma protein therapeutics market size was $27.20 billion in 2021 and is predicted to reach $29.13 billion in 2022 with a CAGR of 7.1%. What is the estimated value of the Plasma Protein Therapeutics Market? The Plasma Protein Therapeutics Market is estimated to reach USD 50.4 billion by 2030, with a CAGR of 7.1 percent throughout the forecasted period. What are the key Plasma Protein Therapeutics Market trends? The rise in the prevalence of autoimmune disorders and the rise in the geriatric population are the key trends in the Plasma Protein Therapeutics Market. Sources https://givingblood.org/about-blood/blood-facts.aspx https://www.niehs.nih.gov/health/topics/conditions/autoimmune/index.cfm https://www.frontiersin.org/articles/10.3389/fmed.2021.684151/full https://www.karger.com/Article/Fulltext/478012 https://www.blood.gov.au/ig-criteria https://www.ajmc.com/view/prevalence-of-hemophilia-worldwide-is-triple-that-of-previous-estimates-new-study-says- https://www1.wfh.org/publications/files/pdf-2045.pdf 1. Introduction 1.1. Study Objective 1.2. Market Definition 1.3. Study Scope 1.3.1. Markets Covered 1.3.2. Geographic Scope 1.3.3. Years Considered 1.3.4. Stakeholders 2. Research Methodology 2.1. Data Procurement 2.2. Paid Database 2.2.1. Secondary Data 2.2.1.1. Key Secondary sources 2.2.2. Primary Data 2.2.2.1 Primary sources 2.2.2.2. Key industry insights 2.2.2.3. Primary interviews with experts 2.2.2.4. Key primary respondent list 2.3. Market Size Estimation 2.4. Bottom-Up and Top-Down Approaches 2.4.1. Bottom-Up Approach 2.4.1.1. Approach for arriving at market size by bottom-up analysis 2.4.2. Top-Down Approach 2.4.2.1. Approach for Capturing Market Size by Top-Down Analysis 2.5. Market Breakdown and Data Triangulation 2.6. Research Methodology 2.7. Risk Assessment 3. Executive Summary 3.1 Plasma Protein Therapeutics Market: Post-Covid-19 3.1.1 Actual Scenario 3.1.2 Pessimistic Scenario 3.1.3 Optimistic Scenario 3.1.4 Market Summary 4. Industry Outlook 4.1 Market Snapshot 4.2 Plasma Protein Therapeutics Market 4.2.1 Market, 2021 – 2030 (USD Million) 4.3 Regional Business Analysis 4.3.1 Market, by region, 2021-2030 (USD Million) 4.4 Product Type Business Analysis 4.4.1 Market, By Product Type, 2021-2030 (USD Million) 4.5 Application Business Analysis 4.5.1 Market, By Application, 2021-2030 (USD Million) 4.6 Value Chain Analysis 4.7 Market Variable Analysis 4.7.1 Market Drivers Analysis 4.7.2 Market Restraints Analysis 4.8 Business Environment Analysis Tool 4.8.1 Market PEST analysis 4.8.2 Market Porter’s analysis 4.9 Penetration & Growth Prospect Mapping 5. Market Dynamics 5.1. Introduction 5.2. Market Dynamics 5.2.1. Drivers 5.2.2. Restraints 5.2.3. Opportunities 5.2.4. Challenges 5.3. Impact of Covid-19 5.4. Value Chain Analysis 5.5. Ecosystem 5.6. Patent Analysis 5.7. Trade Analysis 5.8. Tariff Analysis 5.9. Case Study Analysis 5.10. Porter’s Five Forces Analysis 5.10.1 Threat of New Entrants 5.10.2 Threat of Substitutes 5.10.3 Bargaining Power of Buyers 5.10.4 Bargaining Power of Suppliers 5.10.5 Degree of Competition 5.11. Technology Analysis 5.11.1. Trends in Technology (2014-2020) 5.11.2. Trends in Technology (2021-2028) 5.12. Pricing Analysis 5.12.1. Average Price Trend Analysis (By Region, By Country) 6. Competitive & Vendor Landscape 6.1. Company Market Share Analysis 6.2. Manufacturing Sites, Area Served, Product Type 6.3. Market Competitive Situation and Trends 6.4. Manufacturers Mergers & Acquisitions, Expansion Plans 7. Market: By Product Type Segment Analysis 7.1. Introduction 7.2. Sales Volume & Revenue Analysis (2021-2030) 7.3. C1 esterase Inhibitors 7.3.1. C1 esterase Inhibitors market, 2021-2030 (USD Million) 7.4. Albumins 7.4.1. Albumins market, 2021-2030 (USD Million) 7.5. Immunoglobulins 7.5.1. Immunoglobulins market, 2021-2030 (USD Million) 7.6. Coagulation Factors 7.6.1. Coagulation Factors market, 2021-2030 (USD Million) 7.7. Plasma Derived Factor Viii 7.7.1. Plasma Derived Factor Viii market, 2021-2030 (USD Million) 7.8. Fibrinogen 7.8.1. Fibrinogen market, 2021-2030 (USD Million) 7.9. Alpha-1 proteinase inhibitor 7.9.1. Alpha-1 proteinase inhibitor market, 2021-2030 (USD Million) 7.10. Human serum protein 7.10.1. Human serum protein market, 2021-2030 (USD Million) 8. Market: By Application Segment Analysis 8.1. Introduction 8.2. Sales Volume & Revenue Analysis (2021-2030) 8.3. Hereditary Angioedema 8.3.1. Hereditary Angioedema market, 2021-2030 (USD Million) 8.4. Hemophilia 8.4.1. Hemophilia market, 2021-2030 (USD Million) 8.4.1.1. Hemophilia A market, 2021-2030 (USD Million) 8.4.1.2. Hemophilia B market, 2021-2030 (USD Million) 8.5 Primary Immunodeficiency Disease 8.5.1 Primary Immunodeficiency Disease market, 2021-2030 (USD Million) 8.6 Secondary Immunodeficiency 8.6.1 Secondary Immunodeficiency market, 2021-2030 (USD Million) 8.7 Idiopathic Thrombocytopenic Purpura 8.7.1 Idiopathic Thrombocytopenic Purpura market, 2021-2030 (USD Million) 8.8 Others (Kawasaki disease, GBS, and Chronic Inflammatory Demyelinating Polyneuropathy) 8.8.1 Others (Kawasaki disease, GBS, and Chronic Inflammatory Demyelinating Polyneuropathy) market, 2021-2030 (USD Million) 9. Market: Regional Outlook 9.1 North America 9.1.1. North America Market, By Product Type, 2021-2030 (USD Million) 9.1.4. North America Market, By Application, 2021-2030 (USD Million) 9.1.5. North America Market, by Country, 2021-2030 (USD Million) 9.1.4.1. U.S. 9.1.4.1.1. U.S. Market, By Product Type, 2021-2030 (USD Million) 9.1.4.2. Canada 9.1.4.2.1. Canada Market, By Product Type, 2021-2030 (USD Million) 9.1.4.2.2. Canada Market, By Region, 2021-2030 (USD Million) 9.1.4.2.3. Canada Market, by Applications, 2021-2030 (USD Million) 9.2. Europe 9.2.1. Europe Market, By Product Type, 2021-2030 (USD Million) 9.2.2. Europe Market, by By Application, 2021-2030 (USD Million) 9.2.5. Europe Market, by country, 2021-2030 (USD Million) 9.2.4.1 U.K. 9.2.4.1.1. U.K. Market, By Product Type, 2021-2030 (USD Million) 9.2.4.1.2. U.K. Market, By Applications, 2021-2030 (USD Million) 9.2.4.1.3. U.K. Market, by Region, 2021-2030 (USD Million) 9.2.4.2. Germany 9.2.4.2.1. Germany Market, By Product Type, 2021-2030 (USD Million) 9.2.4.2.2. Germany Market, By Application, 2021-2030 (USD Million) 9.2.4.2.3. Germany Market, by Region, 2021-2030 (USD Million) 9.2.4.3. France 9.2.4.3.1. France Market, By Product Type, 2021-2030 (USD Million) 9.2.4.3.2. France Market, By Region, 2021-2030 (USD Million) 9.2.4.3.3. France Market, by Application, 2021-2030 (USD Million) 9.2.4.4. Rest of Europe 9.2.4.4.1. Rest of Europe Market, By Product Type, 2021-2030 (USD Million) 9.2.4.4.2. Rest of Europe Market, By Region, 2021-2030 (USD Million) 9.2.4.4.3. Rest of Europe Market, by Application, 2021-2030 (USD Million) 9.3. Asia Pacific 9.3.1. Asia Pacific Market, By Product Type, 2021-2030 (USD Million) 9.3.2. Asia Pacific Market, By Application, 2021-2030 (USD Million) 9.3.5. Asia Pacific Market, by country, 2021-2030 (USD Million) 9.3.4.1. China 9.3.4.1.1. China Market, By Product Type, 2021-2030 (USD Million) 9.3.4.1.2. China Market, By Region, 2021-2030 (USD Million) 9.3.4.1.3. China Market, by Application, 2021-2030 (USD Million) 9.3.4.2. India 9.3.4.2.1. India Market, By Product Type, 2021-2030 (USD Million) 9.3.4.2.2. India Market, By Region, 2021-2030 (USD Million) 9.3.4.2.3. India Market, by Application, 2021-2030 (USD Million) 9.3.4.3. Japan 9.3.4.3.1. Japan Market, By Product Type, 2021-2030 (USD Million) 9.3.4.3.3. Japan Market, by Application, 2021-2030 (USD Million) 9.3.4.4. South Korea 9.3.4.4.1. South Korea Market, By Product Type, 2021-2030 (USD Million) 9.3.4.4.3. South Korea Market, by Application, 2021-2030 (USD Million) 9.3.4.5. Rest of ASIA PACIFIC 9.3.4.5.1. Rest of ASIA PACIFIC Market, By Product Type, 2021-2030 (USD Million) 9.3.4.5.3. Rest of ASIA PACIFIC Market, by Application, 2021-2030 (USD Million) 9.4. Latin America 9.4.1. Latin America Market, By Product Type, 2021-2030 (USD Million) 9.4.3. Latin America Market, by Application, 2021-2030 (USD Million) 9.4.4. Latin America Market, by country, 2021-2030 (USD Million) 9.4.4.1. Brazil 9.4.4.1.1. Brazil Market, By Product Type, 2021-2030 (USD Million) 9.4.4.1.3. Brazil Market, by Application, 2021-2030 (USD Million) 9.4.4.2. Mexico 9.4.4.2.1. Mexico Market, By Product Type, 2021-2030 (USD Million) 9.4.4.2.3. Mexico Market, by Application, 2021-2030 (USD Million) 9.4.4.3. Rest of the Latin America 9.4.4.3.1. Rest of the Latin America Market, By Product Type, 2021-2030 (USD Million) 9.4.4.3.3. Rest of the Latin America Market, by Application, 2021-2030 (USD Million) 9.5. MEA 9.5.1. MEA Market, By Product Type, 2021-2030 (USD Million) 9.5.3. MEA Market, by Application, 2021-2030 (USD Million) 10. Competitive Landscape 10.1 Takeda Pharmaceutical Company Ltd 10.1.1. Company overview 10.1.2. Financial performance 10.1.3. Product Portfolio Analysis 10.1.4. Business Strategy & Recent Development 10.2. Octapharma USA Inc 10.2.1. Company overview 10.2.2. Financial performance 10.2.3. Product Portfolio Analysis 10.2.4. Business Strategy & Recent Development 10.3. Grifols, SA 10.3.1. Company overview 10.3.2. Financial performance 10.3.3. Product Portfolio Analysis 10.3.4. Business Strategy & Recent Development 10.4. Biotest AG 10.4.1. Company overview 10.4.2. Financial performance 10.4.3. Product Portfolio Analysis 10.4.4. Business Strategy & Recent Development 10.5. Baxter 10.5.1. Company overview 10.5.2. Financial performance 10.5.3. Product Portfolio Analysis 10.5.4. Business Strategy & Recent Development 10.6. China Biologic Products Holdings Inc 10.6.1. Company overview 10.6.2. Financial performance 10.6.3. Product Portfolio Analysis 10.6.4. Business Strategy & Recent Development 10.7. al Company Ltd 10.7.1. Company overview 10.7.2. Financial performance 10.7.3. Product Portfolio Analysis 10.7.4. Business Strategy & Recent Development 10.8. Octapharma USA Inc 10.8.1. Company overview 10.8.2. Financial performance 10.8.3. Product Portfolio Analysis 10.8.4. Business Strategy & Recent Development 10.9. Shrie Plc 10.9.1. Company overview 10.9.2. Financial performance 10.9.3. Product Portfolio Analysis 10.9.4. Business Strategy & Recent Development 10.10. Grifols SA 10.10.1. Company overview 10.10.2. Financial performance 10.10.3. Product Portfolio Analysis 10.10.4. Business Strategy & Recent Development 10.11. CSL Behring 10.11.1. Company overview 10.11.2. Financial performance 10.11.3. Product Portfolio Analysis 10.11.4. Business Strategy & Recent Development List of Tables (52 Tables) TABLE 1. Market, By Product Type, 2021-2030 (USD Million) TABLE 2. Market FOR C1 esterase Inhibitors, BY REGION, 2021-2030 (USD Million) TABLE 3. Market FOR Albumins, BY REGION, 2021-2030 (USD Million) TABLE 4. Market FOR Immunoglobulins, BY REGION, 2021-2030 (USD Million) TABLE 5. Market FOR Coagulation Factors, BY REGION, 2021-2030 (USD Million) TABLE 6. Market FOR Plasma Derived Factor Viii, BY REGION, 2021-2030 (USD Million) TABLE 7. Market FOR Fibrinogen, BY REGION, 2021-2030 (USD Million) TABLE 8. Market FOR Alpha-1 proteinase inhibitor, BY REGION, 2021-2030 (USD Million) TABLE 9. Market FOR Human serum protein, BY REGION, 2021-2030 (USD Million) TABLE 10. Market, BY APPLICATION, 2021-2030 (USD Million) TABLE 11. Market FOR Hereditary Angioedema, BY REGION, 2021-2030 (USD Million) TABLE 12. Market FOR Hemophilia, BY REGION, 2021-2030 (USD Million) TABLE 13. Market FOR Primary Immunodeficiency Disease, BY REGION, 2021-2030 (USD Million) TABLE 14. Market FOR Secondary Immunodeficiency, BY REGION, 2021-2030 (USD Million) TABLE 15. Market FOR Idiopathic Thrombocytopenic Purpura, BY REGION, 2021-2030 (USD Million) TABLE 16. Market FOR Others (Kawasaki disease, GBS, and Chronic Inflammatory Demyelinating Polyneuropathy), BY REGION, 2021-2030 (USD Million) TABLE 17. Market, BY REGION, 2021-2030 (USD Million) TABLE 18. NORTH AMERICA Market, BY COUNTRY, 2021-2030 (USD Million) TABLE 19. NORTH AMERICA Market, BY Applications, 2021-2030 (USD Million) TABLE 20. NORTH AMERICA Market, By Product Type, 2021-2030 (USD Million) TABLE 21. NORTH AMERICA Market, BY APPLICATION, 2021-2030 (USD Million) TABLE 22. EUROPE Market, BY COUNTRY, 2021-2030 (USD Million) TABLE 23. EUROPE Market, By Product Type, 2021-2030 (USD Million) TABLE 24. EUROPE Market, BY APPLICATION, 2021-2030 (USD Million) TABLE 25. ASIA-PACIFIC Market, BY COUNTRY, 2021-2030 (USD Million) TABLE 26. ASIA-PACIFIC Market, By Product Type, 2021-2030 (USD Million) TABLE 27. ASIA-PACIFIC Market, BY APPLICATION, 2021-2030 (USD Million) TABLE 28. LAMEA Market, BY COUNTRY, 2021-2030 (USD Million) TABLE 29. LAMEA Market, By Product Type, 2021-2030 (USD Million) TABLE 30. LAMEA Market, BY APPLICATION, 2021-2030 (USD Million) TABLE 31. Takeda Pharmaceutical Company Ltd: COMPANY SNAPSHOT TABLE 32. Takeda Pharmaceutical Company Ltd: OPERATING SEGMENTS TABLE 33. Octapharma USA Inc: COMPANY SNAPSHOT TABLE 34. Octapharma USA Inc: OPERATING SEGMENTS TABLE 35. Grifols, SA: COMPANY SNAPSHOT TABLE 36. Grifols, SA: OPERATING SEGMENTS TABLE 37. Biotest AG: COMPANY SNAPSHOT TABLE 38. Biotest AG: OPERATING SEGMENTS TABLE 39. Baxter: COMPANY SNAPSHOT TABLE 40. Baxter: OPERATING SEGMENTS TABLE 41. China Biologic Products Holdings Inc: COMPANY SNAPSHOT TABLE 42. China Biologic Products Holdings Inc: OPERATING SEGMENTS TABLE 43. al Company Ltd: COMPANY SNAPSHOT TABLE 44. al Company Ltd: OPERATING SEGMENTS TABLE 45. Octapharma USA Inc: COMPANY SNAPSHOT TABLE 46. Octapharma USA Inc: OPERATING SEGMENTS TABLE 47. Shrie Plc: COMPANY SNAPSHOT TABLE 48. Shrie Plc: OPERATING SEGMENTS TABLE 49. Grifols SA: COMPANY SNAPSHOT TABLE 50. Grifols SA: OPERATING SEGMENTS TABLE 51. CSL Behring: COMPANY SNAPSHOT TABLE 52. CSL Behring: OPERATING SEGMENTS List of Figures (20 Figures) Figure 1 Market: Research Methodology Steps Figure 2 Research Design Figure 3 Breakdown of Primaries: Market Figure 4 Research Methodology: Hypothesis Building Figure 5 Market: Product-Based Estimation Figure 6 Top 11 Companies with Highest No. Of Patent in Last 9 Years Figure 7 No. Of Patents Granted Per Year, 2019–2020 Figure 8 Import Data for Plasma Protein Therapeutics, By Country, 2016–2020 (USD Thousand) Figure 9 Export Data for Plasma Protein Therapeutics, By Country, 2016–2020 (USD Thousand) Figure 10 Data Triangulation Methodology Figure 11 Market, By Applications, 2019 vs. 2025 (USD Million) Figure 12 Market Share, By Product Type, 2019 vs. 2025 Figure 13 Geographical Snapshot of the Market Figure 14 Immunoglobulins to Witness Higher CAGR in Market for Product Type Segment during Forecast Period. Figure 15 Hemophilia to Witness Higher CAGR in the Market for Application Segment during the Forecast Period. Figure 16 North America Accounted for the Largest Share of the Market, By Regional Basis, in 2019 Figure 17 Market: Drivers, Restraints, Opportunities, and Challenges Figure 18 North America: Market Snapshot Figure 19 Asia Pacific: Market Snapshot Figure 20 Vendor Dive: Evaluation Overview